Skip to main content
Premium Trial:

Request an Annual Quote

Quadrant Biosciences Wins $2.3M NIH Grant to Develop Saliva Test for Concussion

NEW YORK — Quadrant Biosciences said on Monday that it has received a $2.3 million grant from the National Institutes of Health to develop its saliva-based microRNA diagnostic test for concussions in children and adolescents.

Syracuse, New York-based Quadrant has been working with researchers from Penn State University and SUNY Upstate Medical University on saliva-based biomarkers of various neurological conditions. In 2018, they published data linking saliva concentrations of multiple miRNAs with concussion duration and symptoms in children.

With the newly awarded Fast-Track Phase I/II Small Business Technology Transfer grant, Quadrant aims to develop a rapid method for quantifying these biomarkers for potential point-of-care use. It also plans to validate a diagnostic algorithm designed to distinguish mild traumatic brain injury (mTBI) from medical conditions with overlapping symptoms, such as chronic headaches and exercise-related fatigue.

The research will be conducted in a study of 2,500 adolescents and young adults with either a formal diagnosis of an mTBI or an overlapping medical condition, in collaboration with SUNY Upstate, SUNY Buffalo, Arkansas Children's, Children's Hospital of Michigan, and Penn State Medical Centers.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.